The Democratic Republic of Congo (DRC) is grappling with its worst Ebola outbreak to date, with confirmed cases surpassing 3,000. As of July 27, 2026, officials reported 3,075 cases, including 1,354 deaths. The outbreak, declared on May 15, 2026, is caused by the Bundibugyo strain, for which there is currently no approved vaccine or treatment.
The outbreak has primarily affected the northeastern province of Ituri, which borders South Sudan and Uganda. Improved detection and testing have played a crucial role in identifying more infections, leading to a surge of around 1,000 cases in just 10 days. This brings the total number of cases across five provinces to 3,075.
The DRC is facing significant challenges in managing this outbreak. The region has been scarred by decades of violence, complicating response efforts. Additionally, strikes by healthcare workers demanding unpaid wages have disrupted services in some hospitals, further straining the healthcare system.
Efforts to combat the outbreak are ongoing, with scientists racing to develop vaccines and treatments against the Bundibugyo strain. Oxford University recently announced that the first volunteer group had received an experimental vaccine specifically targeting the virus. Several other candidate vaccines are being fast-tracked for clinical trials, and two potential treatments are under development.
The World Health Organization (WHO) has warned that the outbreak could last several more months. With no approved vaccine or treatment currently available, the focus remains on containment, improved detection, and supporting healthcare workers to mitigate the spread of the virus.